Clinical Trials on Nasal Mucosa Hypertrophy in Portugal

Total 77 results

Alma Lasers

Not yet recruiting

Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars.

Acne Scars - Mixed Atrophic and Hypertrophic

Portugal
Portuguese Oncology Institute, Coimbra

Completed

Simethicone and N-acetylcysteine in Upper Endoscopy - Prospective Double-blinded Randomized Controlled Trial

Gastric Mucosal Lesion

Portugal
João Martins Pisco

Completed

Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia

Lower Urinary Tract Symptoms | Prostatic Diseases | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy, Benign | Genital Diseases, Male

Portugal
Bristol-Myers Squibb

Active, not recruiting

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Hypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic Cardiomyopathy

Denmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
Cytokinetics

Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Symptomatic Hypertrophic Cardiomyopathy (HCM)

United States, France, Israel, Spain, United Kingdom, Italy, Portugal, Poland, Hungary, Denmark, Netherlands, Germany, Czechia
MyoKardia, Inc.

Completed

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)

Obstructive Hypertrophic Cardiomyopathy

United States, France, Germany, Czechia, Spain, Belgium, Denmark, Portugal, Netherlands, Israel, Poland, United Kingdom, Italy
Cytokinetics
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM) (SEQUOIA-HCM)

Obstructive Hypertrophic Cardiomyopathy (oHCM)

United States, France, Spain, Portugal, Germany, China, United Kingdom, Israel, Netherlands, Denmark, Czechia, Hungary, Italy, Poland
Jean-Luc Balligand
University of Oxford; University of Athens; Cliniques universitaires Saint-Luc-... and other collaborators

Active, not recruiting

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure (Beta3_LVH)

Hypertrophy, Left Ventricular

Belgium, France, Germany, Greece, Italy, Poland, Portugal, United Kingdom
Instituto de Ciências Biomédicas Abel Salazar

Completed

Evaluation of the Functional Impact of Adenotonsilectomy

Infections | Tonsillitis | Apnea, Obstructive | Tonsillar Hypertrophy | Respiratory Function Impaired | ENT Disorder

Portugal
Bristol-Myers Squibb

Active, not recruiting

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

Cardiomyopathy, Hypertrophic

Spain, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Israel, Japan, Netherlands, Norway, Poland, Portugal, United Kingdom, United States, Australia, China, Czechia, India, Italy, Korea, Republic of
Campus Neurológico Sénior

Completed

Immersive Virtual Reality for the Non-pharmacological Management of Parkinson's Disease

Parkinson Disease

Portugal
Centro Hospitalar de Lisboa Central

Not yet recruiting

Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson's Disease Walking in Parkinson's Disease.

Parkinson Disease | Botulinum Toxin | Freezing of Gate

Portugal
Campus Neurológico Sénior
Johns Hopkins University

Completed

The Feasibility and Efficacy of an Immersive Virtual Reality Software in Parkinson's Disease Patients

Parkinson Disease

Portugal
Campus Neurológico Sénior
University of Lisbon

Completed

Feasibility of the AHA Exergame System in Parkinson's Disease Patients

Parkinson Disease

Portugal
Pfizer

Completed

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology (TTRACK)

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Italy, Romania, France, Australia, Austria, Portugal, Slovakia, Slovenia, Spain, United Kingdom
Albino Maia
Centro Hospitalar Lisboa Ocidental; Centro Hospitalar De São João, E.P.E.; Centro... and other collaborators

Recruiting

Deep Brain Stimulation-Induced Mania in Parkinson's Disease (BPD_DBS)

Parkinson Disease | Mania

Portugal
Bial - Portela C S.A.

Active, not recruiting

OpicApone Sleep dISorder (OASIS)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of Food on BIA 6-512 (Trans-resveratrol)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. (BIPARKII)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Sanofi

Completed

Clinical Trial in Males With BPH (Enlarged Prostate)

Prostatic Hyperplasia | Urinary Retention | Benign Prostatic Hypertrophy

United States, Canada, Poland, Romania, Australia, Netherlands, Portugal, Spain, Sweden, Bulgaria, Denmark, Finland, Hungary, Norway, South Africa, Greece, Israel
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Parkinson's Disease

Portugal, Romania, Ukraine
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Juvantia Pharma Ltd
Santhera Pharmaceuticals

Unknown

Fipamezole in Neurogenic Orthostatic Hypotension (Foehn)

Parkinson's Disease | Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension (NOH)

France, Portugal
NeuraLight
European Clinical Research Infrastructure Network

Recruiting

Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease (PALOMA)

Parkinson Disease

United States, Switzerland, Portugal, United Kingdom, Spain
Centre National de la Recherche Scientifique, France
Instituto de Medicina Molecular João Lobo Antunes

Unknown

Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison (FraLusoPark)

Disease Progression | Parkinson's Disease | Dysarthria | Speech | Medical Treatment | Cross-language

France, Portugal
Abbott Products

Terminated

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Advanced Stage Parkinson's Disease

Germany, Italy, Portugal
University College, London
Lund University; University Hospital, Bordeaux; Ludwig-Maximilians - University... and other collaborators

Completed

Care for Late Stage Parkinsonism (CLaSP)

Parkinson's Disease | Late Stage Parkinson's Disease

Netherlands, United Kingdom, Germany, France, Portugal, Sweden
Hoffmann-La Roche

Completed

STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Basal Cell Carcinoma

Italy, Czechia, Hungary, Belgium, Canada, Ireland, Mexico, Portugal, Slovenia, Spain, Turkey, Brazil, Bosnia and Herzegovina, Romania, United Kingdom, Germany, Israel, France, Greece, Russian Federation, Lithuania, Netherlands, Norway, Colomb... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps (SINUS-52)

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

Belgium, Mexico, Turkey, Israel, Spain, Sweden, Argentina, Canada, Japan, United States, Australia, Chile, Portugal, Russian Federation
Sanofi

Completed

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

Parkinson Disease

France, Canada, Germany, Netherlands, Portugal, Spain, Sweden, Tunisia, Denmark, Morocco, South Africa, Austria, United Kingdom
University Hospital, Lille
European Commission; ApoPharma

Completed

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII)

Parkinson Disease

Netherlands, Spain, France, Portugal, Czechia, United Kingdom, Austria, Germany
Ionis Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) (HORIZON)

Multiple System Atrophy

Austria, Portugal, France, Germany, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in CRSsNP (Liberty CRSsNP)

Chronic Sinusitis | Sinusitis | Chronic Rhinosinusitis Without Nasal Polyps | Sinus Disorder | Respiratory Disorder

Belgium, Spain, Argentina, Ukraine, Portugal, China, United States, Canada, Chile, Hungary, Korea, Republic of, Russian Federation, Sweden
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients (EVEREST)

Asthma | Chronic Rhinosinusitis With Nasal Polyps

Belgium, Czechia, France, Italy, Canada, Mexico, Denmark, Spain, Hungary, Sweden, United States, Finland, Germany, Poland, Portugal, Romania, United Kingdom
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
Hoffmann-La Roche

Completed

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps (POLYP 1)

Nasal Polyps | Chronic Rhinosinusitis

Czechia, United States, Portugal, Germany, Canada, Ukraine, Poland, Mexico, Russian Federation, United Kingdom

Clinical Trials on Nasal Mucosa Hypertrophy in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations